Health Condition 1: J352- Hypertrophy of adenoids
Conditions
Interventions
Intervention1: Omalizumab: Inj Omalizumab subcutaneously 4 weekly for 3 doses dose based on body weight and serum IgE levels
Control Intervention1: Nasal corticosteroid and oral antihistaminics: Aqueo
Sponsors
AIIMS DELHI
Eligibility
Inclusion criteria
Inclusion criteria: Age 5 to 14 years Symptomatic adenoid hypertrophy with at least one of these symptoms like mouth breathing or snoring or nasal obstruction or OSA or OME or recurrent ASOM or sinusitis and grade 3 or 4 adenoid hypertrophy Serum IgE levels more than 50 IU per mL with or without allergic symptoms like excessive sneezing or rhinorrhea or atopy or itching
Exclusion criteria
Exclusion criteria: Obstructive sleep apnoea with Pulmonary hypertension or cor pulmonale Lysosomal storage disorders or any other diseases which mandate urgent need for surgical intervention for adenoid hypertrophy Adenoid hypertrophy and serous otitis media resulting in sensorineural hearing loss
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the effect of nasal steroids and oral antihistaminics vs parenteral omalizumab on the nasopharyngoscopic findings in pediatric patients with symptomatic adenoid hypertrophyTimepoint: Baseline, 3 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the effect of nasal steroids and oralantihistaminics vs parenteral omalizumab on symptomatology.Timepoint: 3 months | — |
Countries
India
Contacts
Public ContactDR MANPREET
AIIMS NEW DELHI
Outcome results
None listed